Chong Kun Dang Bio, a subsidiary of Chong Kun Dang, is developing a microbiome-based acne treatment that overcomes both antibiotic resistance and cold-chain logistics limitations. The heat-killed, non-living formulation retains potent antibacterial and anti-inflammatory effects, offering a stable, easy-to-ship alternative for dermatological and cosmetic applications. This innovation targets a high-demand market segment where traditional antibiotics face growing resistance and side-effect concerns.
Technology and mechanism
The company has secured a proprietary composition containing three beneficial bacterial strains isolated from healthy human skin: *Staphylococcus epidermidis*, *Streptococcus salivarius*, and *Dermacoccus profundi*. These strains directly antagonize the primary acne pathogen *Cutibacterium acnes*. In vitro co-culture experiments showed that live *S. epidermidis* inhibited pathogen growth by 38.0% compared to controls, while *S. salivarius* and *D. profundi* achieved 10.8% and 11.4% inhibition, respectively.
Beyond pathogen suppression, the strains modulate excessive immune inflammation around acne lesions. In keratinocyte-based anti-inflammatory assays, the composition reduced expression of COX-2 and iNOS enzymes, as well as pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8. In vivo animal models, topical application of heat-killed bacteria alleviated swelling and erythema.
Regulatory and safety advantages
A key regulatory hurdle for live biotherapeutic products is the risk of horizontal antibiotic resistance gene transfer. Chong Kun Dang Bio addressed this by performing whole-genome sequencing (WGS) on the three strains, confirming the absence of plasmids or insertion sequences that could transfer resistance genes to other human pathogens. This safety data strengthens the path toward regulatory approval.
Commercial and supply-chain benefits
The most commercially significant feature is that the composition retains efficacy even after heat sterilization, eliminating the need for cold-chain storage and transport. Unlike live probiotics, which require strict temperature control, the heat-killed format allows easy formulation into creams, ointments, and other skincare products. This reduces logistics costs and expands distribution options for overseas buyers.
What buyers should watch
Chong Kun Dang Bio has prior experience commercializing microbiome ingredients such as Cutibiome and Reliefbiome in the B2B cosmetic raw material market. The company is expected to develop this acne treatment composition into either a prescription topical drug for dermatology or a dermocosmetic product. Importers and distributors should monitor patent registration progress and potential licensing opportunities for this heat-killed microbiome platform, which addresses both efficacy and cold-chain pain points in the acne treatment supply chain.
Source: Read the original report | Published: June 09, 2026